Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma and Immunology

Published: 2025-05-02 09:06:47 ET ATXS

Published on 05/02/2025 at 09:06

BOSTON - Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart's potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (HAE) with dosing every 3 and 6 months have been published in the Annals of Allergy, Asthma & Immunology.

'We are thrilled by our publication in the Annals of Allergy, Asthma & Immunology and the opportunity to provide additional information that affirms our belief in navenibart's potential to become the first-choice therapy for HAE,' said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. 'The Phase 1a trial in healthy subjects laid the foundation for the advancement of navenibart and charted a path toward initiating ALPHA-ORBIT, our currently enrolling pivotal Phase 3 trial. The Phase 3 program, designed to introduce a potentially life-changing HAE therapy to eligible participants around the globe, is underway.'

Overview of results from the Phase 1a trial of navenibart in healthy subjects

For all doses =300 mg, navenibart mean half-life ranged from 82 to 105 days, supporting the potential for administration every 3 and 6 months. Navenibart's inhibition of plasma kallikrein activity versus placebo was statistically significant (P